MDASI Multiple Myeloma Module
The MD Anderson Symptom Inventory for multiple myeloma (MDASI-MM) is a disease-specific module. Use the MDASI-MM to assess the severity of symptoms experienced by patients with multiple myeloma and the interference with daily living caused by these symptoms.
Along with the core MDASI’s 13 symptom items and 6 interference items, the MDASI-MM also assesses 7 symptoms specific to multiple myeloma.
| Core MDASI Symptoms | Multiple Myeloma Symptoms | MDASI Interference |
|---|---|---|
| Pain | Bone aches | Relations with other people |
| Fatigue | Muscle weakness | Enjoyment of life |
| Nausea | Sore mouth or throat | Mood |
| Disturbed sleep | Rash | Walking |
| Distress (feeling upset) | Difficulty concentrating | Activity |
| Shortness of breath | Constipation | Work (including housework) |
| Difficulty remembering | Diarrhea | |
| Lack of appetite | ||
| Drowsiness | ||
| Dry mouth | ||
| Sadness | ||
| Vomiting | ||
| Numbness/tingling |
Order the MDASI-MM
Use our convenient online form to order the MDASI-MM for use in your clinical research, clinical practice, funded and non-funded academic research, commercial research, or reproduction in educational materials or other publications.
MDASI-MM Features
- Purpose: To assess the severity of multiple myeloma-related symptoms and the impact of these symptoms on daily functioning
- Population: Patients with symptoms caused by multiple myeloma and its treatment
- Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
- Method: Self-report or interview with research staff; paper-and-pencil or electronic data entry*
- Time required: Five minutes or less
- Scoring: Please see the MDASI User Guide
- Reliability: Cronbach alpha reliability ranges from 0.85 to 0.91
*Electronic data capture offers several benefits:
- Allows symptom monitoring when the patient is away from the hospital
- Is convenient for patients, who can choose web access, personalized patient portals, or smartphones to access questionnaires
- Minimizes missing data, especially in longitudinal studies
- Provides accurate, real-time symptom data at expected time points
- Generates immediate feedback, potentially allowing caregivers to address severe symptoms more effectively
MDASI-MM Language Versions
Click on a linked language to view a sample in PDF format.
Don't see a language you need? Contact us at symptomresearch@mdanderson.org.
| Psychometrically and Linguistically Validated | Linguistically Validated |
|---|---|
| English | Arabic |
| Chinese (Simplified) (in process) | |
| Czech | |
| Danish | |
| Dutch | |
| French | |
| German | |
| Greek | |
| Hebrew | |
| Hungarian | |
| Italian | |
| Japanese | |
| Norwegian | |
| Polish | |
| Portuguese (Portugal) |
|
| Romanian | |
| Russian | |
| Spanish | |
| Swedish | |
| Turkish |
MDASI User's Guide
In response to the US Food and Drug Administration's 2009 guidance for the pharmaceutical industry on the use of patient-reported outcomes measures in medical product development to support labeling claims, we have prepared a MDASI User Guide to document the development and psychometric properties of the MDASI and its modules. The User Guide addresses the recommendations in the FDA guidance and establishes the MDASI's adequacy as a measure to support medical product claims.
Selected MDASI-MM References
Validation
Jones D, Vichaya EG, Wang XS, et al. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol 6(1):13, 2013.
Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer: the M. D. Anderson Symptom Inventory. Cancer 89:634-1646, 2000.
Clinical Application
Weisel K, Dimopoulos MA, San-Miguel J, et al. Impact of elotuzumab plus pomalidomide/dexamethasone on health-related quality of life for patients with relapsed/refractory multiple myeloma: final data from the phase 2 ELOQUENT-3 Trial. Hemasphere 7(3):e843, 2023.
Koevoets EW, Schagen SB, de Ruiter MB, et al.; PAM study group. Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study). Breast Cancer Res 24(1):36, 2022.
Wang XS, Shi Q, Mendoza TR, et al. Minocycline for symptom reduction in patients with multiple myeloma during maintenance therapy: a phase II placebo-controlled randomized trial. Support Care Cancer 29(10):6099-6107, 2021.
Kamal M, Wang XS, Shi Q, et al. Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma. Support Care Cancer 29(1):467-475, 2021.
Shi Q, Wang XS, Li G, et al. Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer 121(7):1138-1146, 2015.
Wang XS, Shi Q, Shah ND, et al. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res 20(5):1366-1374, 2014.
Methodology
Wang T, Lu Q, Tang L. Assessment tools for patient-reported outcomes in multiple myeloma. Support Care Cancer 31(7):431, 2023.
Every MDASI module contains:
all 13 MDASI core symptoms...
pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, difficulty remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness/tingling
...and all 6 MDASI interference items
general activity, mood, work, relations with others, walking, enjoyment of life
The MDASI-MM is one of the most widely used patient-reported outcomes assessment tools designed specifically for multiple myeloma. The MDASI-MM's items were derived from patient and clinician input plus literature review and tested in two therapeutic modalities (induction chemotherapy and stem cell transplant).
Sheeba K. Thomas, M.D.
Professor, Lymphoma-Myeloma